Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 106: HIV-1 DNA Priming Regimens with MVA-CMDR Boosts
NCT02296541Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DNA Nat-B env, DNA CON-S env, DNA Mosaic env vaccine and MVA-CMDR in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2014; status: completed.
02
Drugs
DNA Nat-B envDNA CON-S envDNA Mosaic env vaccineMVA-CMDR
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02296541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296541.